GetTopicDetailResponse(id=96f53934901, topicName=吳小華, introduction=吳小華, content=null, image=null, comments=4, allHits=1240, url=https://h5.medsci.cn/topic?id=39349, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=98461, tagList=[TagDto(tagId=98461, tagName=吳小華)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1748071, encodeId=41391e480710d, content=<a href='/topic/show?id=96f53934901' target=_blank style='color:#2F92EE;'>#吳小華#</a>, objectTitle=J Immunother Cancer：復(fù)腫吳小華教授團(tuán)隊(duì)研究表明卡瑞利珠單抗聯(lián)合法米替尼（famitinib）可作為鉑類耐藥復(fù)發(fā)卵巢癌治療有效方案, objectType=article, longId=294001, objectId=19182940012d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19182940012d, replyNumber=0, likeNumber=86, createdTime=2022-05-29, rootId=0, userName=chenshujs, userId=a0d536034515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19182940012d, moduleTitle=J Immunother Cancer：復(fù)腫吳小華教授團(tuán)隊(duì)研究表明卡瑞利珠單抗聯(lián)合法米替尼（famitinib）可作為鉑類耐藥復(fù)發(fā)卵巢癌治療有效方案, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=19182940012d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1748070, encodeId=e7ea1e4807082, content=<a href='/topic/show?id=96f53934901' target=_blank style='color:#2F92EE;'>#吳小華#</a>, objectTitle=吳小華教授：2021年度宮頸癌診治年度進(jìn)展, objectType=article, longId=293804, objectId=51fa29380403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fa29380403, replyNumber=0, likeNumber=99, createdTime=2022-08-01, rootId=0, userName=chenshujs, userId=a0d536034515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fa29380403, moduleTitle=吳小華教授：2021年度宮頸癌診治年度進(jìn)展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=51fa29380403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1748069, encodeId=8c6e1e48069c6, content=<a href='/topic/show?id=96f53934901' target=_blank style='color:#2F92EE;'>#吳小華#</a>, objectTitle=吳小華：2019年宮頸癌研究進(jìn)展盤點(diǎn), objectType=article, longId=185731, objectId=efaf185e31a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efaf185e31a9, replyNumber=0, likeNumber=82, createdTime=2020-07-01, rootId=0, userName=chenshujs, userId=a0d536034515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efaf185e31a9, moduleTitle=吳小華：2019年宮頸癌研究進(jìn)展盤點(diǎn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=efaf185e31a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1748068, encodeId=45d21e48068da, content=<a href='/topic/show?id=96f53934901' target=_blank style='color:#2F92EE;'>#吳小華#</a>, objectTitle=ASCO 2014：吳小華談復(fù)發(fā)卵巢癌聯(lián)合靶向治療試驗(yàn), objectType=article, longId=35714, objectId=b98435e1424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b98435e1424, replyNumber=0, likeNumber=106, createdTime=2015-03-02, rootId=0, userName=chenshujs, userId=a0d536034515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b98435e1424, moduleTitle=ASCO 2014：吳小華談復(fù)發(fā)卵巢癌聯(lián)合靶向治療試驗(yàn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b98435e1424)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
